topic

654 Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors
Nerea Lopetegui Lia, Syed Imran Jafri, Khalid Shalaby, Dimitrios Drekolias, James Vredenburgh

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A392-A393; DOI: 10.1136/jitc-2020-SITC2020.0654
655 Concordance between healthcare providers and expert consensus recommendations in the management, monitoring, and mitigation of adverse events associated with CAR T-cell therapy: an updated analysis
Matthew Frigault, Megan Cartwright, Krista Marcello, Timothy Quill, Daniel DeAngelo, Ilene Galinsky, Shilpa Paul, Jae Park

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A393-A394; DOI: 10.1136/jitc-2020-SITC2020.0655
657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma
Chantal Saberian, Faisal Fa’ak, Jean Tayar, Maryam Buni, Sang Kim, Huifang Lu, Maria Suarez-Almazor, Stephen Gruschkus, May Daher, Kaysia Ludford, Daniel Johnson, Noha Abdel-Wahab, Adi Diab

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A394; DOI: 10.1136/jitc-2020-SITC2020.0657
656 Time to diagnostic clarity for suspected checkpoint-inhibitor pneumonitis in patients with lung cancer
Eric Olson, Andrew Faucheux, JiaHao Liang, Janardhana Ponnatapura, Jeffrey Lantz, Nathan Roberts, Andy Dothard, Thomas Lycan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A394; DOI: 10.1136/jitc-2020-SITC2020.0656
659 Blocking cytokine IL-1 with anakinra for the prevention of cytokine release syndrome in COVID-19
Erik Soule, Jason Williams, Matthias Piesche

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A395-A396; DOI: 10.1136/jitc-2020-SITC2020.0659
661 Five immunotypic signatures identified in human glioblastoma correlate with tumor contact with the lateral ventricle, immune suppression, and patient outcome
Todd Bartkowiak, Sierra Barone, Madeline Hayes, Allison Greenplate, Justine Sinnaeve, Nalin Leelatian, Akshitkumar Mistry, Caroline Roe, Bret Mobley, Lola Chambless, Reid Thompson, Kyle Weaver, Rebecca Ihrie, Jonathan Irish

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A396-A397; DOI: 10.1136/jitc-2020-SITC2020.0661
660 Developing generalizable deep learning models for tumor segmentation in pathology images to enable the identification of predictive biomarkers for immunotherapies
Qinle Ba, Peng Yang, Jennifer Yearley

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A396; DOI: 10.1136/jitc-2020-SITC2020.0660
662 Statistical learning from clinical and immunogenomic variables to predict response and survival with PD-L1 inhibition in advanced urothelial cancer
Wolfgang Beck, Tracy Rose, Matthew Milowsky, William Kim, Jeff Klomp, Benjamin Vincent

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A397-A398; DOI: 10.1136/jitc-2020-SITC2020.0662
665 Spatial single-cell analysis of colorectal cancer tumour using multiplexed imaging mass cytometry
Minh Tran, Andrew Su, HoJoon Lee, Richard Cruz, Lance Pflieger, Ashely Dean, Quan Nguyen, Hanlee Ji, Terence Rhodes

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A399; DOI: 10.1136/jitc-2020-SITC2020.0665
666 Analyzing regulatory requirements in the development of immune checkpoint inhibitors using Artificial Intelligence
Krish Perumal, Amin Osmani

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A399-A400; DOI: 10.1136/jitc-2020-SITC2020.0666

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages